Prothena
PRTA
Prothena (PRTA) news
Recent news
Prothena: May earn $55 mln clinical milestone payment if Bristol Myers Squibb decides to advance PRX019; BMS decision expected year end 2026
Prothena Corporation plc (NASDAQ: PRTA) has completed the Phase 1 study for PRX019, a potential treatment for neurodegenerative diseases being developed in collaboration with Bristol Myers Squibb (BMS). The company could potentially earn a $55 million clinical milestone payment if BMS decides to…
AInvest Wire · Aug 6, 2026ImportantProthena earned $50 million milestone payment from Novo Nordisk
AInvest Wire · Mar 9, 2026ImportantProthena preparing for a potential sale - Bloomberg
AInvest Wire · Oct 16, 2023ImportantBiotech firm Prothena is said to prepare for potential sale.
AInvest Wire · Oct 16, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.